DeepView® System Highlighted at the 2026 British Burn Association Annual Conference
Rhea-AI Summary
Spectral AI (Nasdaq:MDAI)/b) highlighted its DeepView® System at the 2026 British Burn Association conference in Nottingham, featuring multiple podium and poster presentations. Dr. Jeffrey Carter’s paper on multispectral imaging with AI for burn wounds received BBA’s 1st Prize oral presentation award.The company noted prior FDA De Novo Classification for DeepView in May 2026 and initial UKCA authorization in February 2024. DeepView is a non-invasive, AI-driven device providing rapid, data-based assessments of burn wound healing potential, trained on over 340 billion pixels of image data.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MDAI
On the day this news was published, MDAI gained 0.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
MDAI was down -2.92% pre-announcement while momentum peers showed mixed action: CTSO up, ICCM down. With gains and losses among close medical device peers, this points to stock-specific factors rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 12 | Awareness partnership | Positive | -1.6% | Partnering on Wound Healing Awareness Month and highlighting FDA-cleared DeepView System. |
| Jun 11 | Conference participation | Positive | +1.6% | Announcement of DeepView showcase and multiple presentations at BBA conference. |
| Jun 01 | Annual meeting results | Neutral | -1.9% | All AGM proposals approved and operational/funding milestones highlighted. |
| May 26 | Regulatory clearance | Positive | -11.6% | FDA De Novo Classification for DeepView burn indication enabling US commercial distribution. |
| May 12 | Earnings update | Negative | -5.1% | Q1 2026 revenue decline, net loss, but reiterated full-year revenue guidance. |
News on DeepView and partnerships has often seen mixed or even negative price reactions, including a sharp selloff after FDA De Novo clearance.
Regulatory & Risk Context
Reported short interest reflects relatively low short positioning, suggesting limited short-squeeze potential but also a moderate baseline for volatility driven mainly by fundamental or news-related factors.
An effective S-3 resale registration allows existing warrant holders to register and potentially sell up to 4,989,502 shares, with proceeds from any resales going to the selling stockholders rather than the company.
Market Pulse Summary
This announcement reinforces DeepView’s visibility, with multiple BBA presentations and prior FDA De Novo and UKCA clearances highlighting its clinical positioning. Investors may watch for evidence of adoption, reimbursement progress, and how financing structures influence future shareholder dilution risk.
Key Terms
de novo classification regulatory
ukca regulatory
multispectral imaging medical
ai algorithm technical
medical device technical
AI-generated analysis. Not financial advice.
Dr. Jeffrey Carter Awarded BBA Oral Presentation 1st Prize for his Paper on the Use of Multi-Spectral Imaging with Artificial Intelligence for Burn Wounds
DALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the British Burn Association (BBA) Annual Conference, held on June 17th – 19th at the Nottingham Trent University, Nottingham, England.
The Company’s DeepView® System was on display and was the subject of multiple podium and poster presentations during the conference, highlighting its contributions to advancing burn care through advanced diagnostic analysis across the globe. The presentation from Dr. Jeffrey Carter regarding the use of multispectral imaging with artificial intelligence for burn wounds received first prize at the BBA conference. The Company’s innovative, first-of-its-kind burn wound assessment technology was granted De Novo Classification by the U.S. Food and Drug Administration in May 2026 and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024.
Key Presentations at the BBA Annual Conference:
- Results from the Training & Validation Studies: Multi-Spectral Imaging with Artificial Intelligence for Burn Wounds – Dr. Jeffrey Carter, Louisiana State University Health Science Center, which was awarded 1st Prize by the BBA.
- Artificial Intelligence-Enhanced Multispectral Imaging for Burn Wound Assessment: A Multi-Centre UK Evaluation update – Mr. Shreyas Supparamaniam, Pinderfields General Hospital, Wakefield, UK.
- The role of DeepView imaging in burn surgery decision-making: a patient centred mixed-methods service evaluation – Dr Zoe Gotts, Newcastle Hospitals NHS Foundation Trust.
- Artificial-intelligence enhanced multispectral imaging for burn wound assessment: pilot evaluation of complex anatomical sites – Mr. Poh Hong Tan, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
- Usability of an Artificial Intelligence-Enhanced Multispectral Imaging Tool for Burn Assessment: A Retrospective Heuristic Evaluation – Hajar Abdulla, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
Among the key presentations, Mr. Shreyas Supparamaniam, Plastic Surgery Research Registrar at the Pinderfields General Hospital based in Wakefield, UK shared his experience with the DeepView System. His presentation highlighted the real-world impact of the DeepView System in aiding physicians in the management of thermal burn wounds.
“Our positive experience supports that DeepView has the potential to transform burn care. The device provides an immediate and objective assessment of a wound’s healing potential, enabling us to make more informed treatment decisions. We are excited about this diagnostic innovation and believe in its potential to improve patient care,” said Mr. Supparamaniam.
Dr. Jeffrey Carter added, “It is a tremendous honor to receive First Prize at the BBA Conference for my presentation highlighting clinical outcomes associated with the use of the DeepView System. The meeting also featured compelling real-world evidence from researchers in the United Kingdom that further validated the technology’s performance. The growing body of evidence supporting DeepView underscores its potential to enhance burn assessment and decision-making worldwide.”
The British Burn Association Conference is a premier event that brings together leading clinicians, researchers, and innovators in burn care. The Company’s participation and presence in multiple sessions reinforces its prominent role in driving advancements in the field and supporting healthcare professionals in delivering better outcomes for burn patients.
J. Michael DiMaio, M.D., Chairman of the Board of Spectral AI, expressed pride in the Company’s role at the conference in which he attended, “We’re grateful to see our Company featured so prominently at the British Burn Association Conference year after year. The positive feedback we receive from physicians continues to fuel our mission to revolutionize burn care.”
About the DeepView System
Spectral AI's DeepView System is a non-invasive, predictive medical device which combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within the burn wounds. The DeepView System provides physicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
Devin.Sullivan@theequitygroup.com
Conor Rodriguez
Associate
Conor.Rodriguez@theequitygroup.com
